US · Healthcare · Biotechnology
EPS came in at 2.27 against a street estimate of 2.17 — a beat of 4.6%.
Analysts rate Halozyme Therapeutics Inc a buy (7 buy, 2 hold, 0 sell out of 9) with an average price target of $108.89.
CONFIDENT Record Q2 with royalty revenue +50% YoY to $308M; raised FY26 guidance on strong ENHANZE portfolio expansion and six new partnership deals. Hypercon emerging as second platform engine. Q2 2026 Call did not segment results by geographic region. Analysts pressed on H2 guidance pacing, target exclusivity post-patent, and Hypercon timing/manufacturing. Management confirmed sequential growth, flexible exclusivity structures, and multiple 2027 starts with 5-7 launches by mid-2030s. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 11.69% |
| Vanguard Capital Management, LLC | 4.71% |
| Vanguard Portfolio Management, LLC | 4.67% |
| State Street Corp | 4.56% |
| Amvescap Plc. | 2.80% |
| Morgan Stanley - Brokerage Accounts | 2.50% |
| Boston Partners Global Investors, Inc | 2.44% |
| Bank of America Corp | 2.41% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $492,974 thousand, up from $354,264 thousand in the third quarter of 2025. • Nine-month 2026 reven | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 total revenue rose 39% year over year to $493.0 million, from $354.3 million. • Royalty revenue increased 44% | 2026-11-05 |
| Board / officer change · Q3 2026 HEADLINE NUMBERS • Halozyme Therapeutics filed a Form 8-K dated September 28, 2026, reporting the election of James Daly to its Board of Directors. | 2026-09-30 |
| Material agreement · Q3 2026 HALOZYME THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Total Convertible Notes Issued: $1,500.0 million aggregate principal amount of 1.50% Co | 2026-09-22 |
| Company announcement · Q3 2026 HALOZYME THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company announced pricing of $1.3 billion aggregate principal amount of convertibl | 2026-09-18 |
| Company announcement · Q3 2026 HALOZYME THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company proposes to offer $1.05 billion aggregate principal amount of convertible | 2026-09-16 |
| Board / officer change · Q3 2026 HALOZYME THERAPEUTICS, INC. - FORM 8-K SUMMARY OTHER NOTABLE POINTS • Board Appointment: Dannielle Appelhans was elected to the Board of Directors o | 2026-08-18 |
| Quarterly report · Q2 2026 HALOZYME THERAPEUTICS, INC. — 10-Q SUMMARY FOR Q2 2026 HEADLINE NUMBERS • Total revenues Q2 2026: $481.0 million (up 48% from $325.7 million in Q2 2 | 2026-08-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| 2026 financial guidance and 2025 preliminary revenue estimates provided Halozyme Therapeutics released preliminary 2025 financial estimates on January 28, 2026. The company projects 2025 total revenue between $1.385-$1.400 billion, consisting of: royalties ($865 | 2026-01-28 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Halozyme Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.